AXN-027
Epilepsy, Pain, and other CNS pathologies
Phase 1Active
Key Facts
Indication
Epilepsy, Pain, and other CNS pathologies
Phase
Phase 1
Status
Active
Company
About Axonis Therapeutics
Axonis Therapeutics is a private, clinical-stage biotech pioneering a novel approach to neurological disorders by potentiating the KCC2 transporter to restore functional inhibition in the brain. The company has advanced its lead candidate, AXN-027, into first-in-human trials in 2024, backed by a robust $115 million Series A financing round and a world-class team of experts. With a proprietary KCC2 discovery engine and a focus on high-need conditions like epilepsy and pain, Axonis is positioned to unlock a new therapeutic modality in a potential blockbuster drug space.
View full company profile